Table 1. Pharmacokinetic parameters following intravenous and oral administration of 1, 2 and 5 kDa PEG-coated gold nanoparticles.
| PEG-coated gold nanoparticle |
|||
|---|---|---|---|
| Parameter | 1 kDa | 2 kDa | 5 kDa |
| Intravenous administration (0.8 mg/kg) | |||
| T½ (h) | 17.4 ± 2.8 | 13.2 ± 7.2 | 7.3 ± 2.0 |
| CL (mL/h) | 0.55 ± 0.09 | 0.54 ± 0.32 | 1.91 ± 2.44 |
| Vd (mL) | 12.6 ± 0.7 | 8.2 ± 0.9 | 22.8 ± 31.6 |
| AUC0 to infinity (h*ng/L) | 296,700 ± 49,200 | 364,800 ± 174,500 | 227,700 ± 175,900 |
| Oral administration (8 mg/kg) | |||
| AUC0 to infinity (h*ng/L) | 3,000 ± 1,510A | 858 ± 170B | 263 ± 126B |
| F | 0.0010 | 0.00023 | 0.00035 |
Results are expressed as mean ± SD; N = 3 for intravenous doses and N = 5 for oral doses.
T ½: half-life; CL: clearance; Vd: volume of distribution; AUC: area under the blood concentration versus time curve; F: bioavailability.
Blood concentration data were analyzed using Phenix software using a non-compartmental approach. Different letter superscripts indicate significant differences among groups, p < 0.05.